Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.

@article{Kamm2009EffectOE,
  title={Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.},
  author={M. Kamm and Gary R. Lichtenstein and W J Sandborn and Stefan Schreiber and Kirstin Lees and Karen B. Barrett and Raymond E Joseph},
  journal={Inflammatory bowel diseases},
  year={2009},
  volume={15 1},
  pages={1-8}
}
BACKGROUND Many patients with ulcerative colitis (UC) respond to mesalamine therapy within 8 weeks. Those not achieving remission after 8 weeks are often treated with steroids or other immunosuppressive therapies. This study aimed to determine the effect of 8 weeks' high-dose MMX mesalamine extension therapy in patients with active, mild-to-moderate UC who had previously failed to achieve complete remission in 2 phase III, double-blind, placebo-controlled studies of MMX mesalamine (SPD476-301… CONTINUE READING